CAR Expression Test Services

Are you encountering obstacles in accurately validating CAR expression, maintaining consistent product quality, or complying with evolving regulatory standards in your cell therapy development? Creative Biolabs' CAR Expression Test Services deliver end-to-end analytical support to accelerate your CAR-T program. Using state-of-the-art methodologies including high-resolution flow cytometry, quantitative PCR, and proprietary detection reagents, we ensure robust characterization and lot-release readiness. Our tailored solutions provide the critical evidence needed to advance your candidates smoothly through development and toward successful regulatory submission.

Introduction

The evaluation of CAR expression is a fundamental quality control step in the development of CAR-T cell therapies. High and consistent CAR expression is directly correlated with the efficacy and potency of the therapeutic product. Assessing this expression is critical for optimizing CAR construct design, monitoring transduction efficiency, and ensuring the final product meets the necessary standards for preclinical studies and regulatory submissions.

Fig.1 Multiscale assays for CAR expression and function analysis.^1,4

CAR Expression Test Services at Creative Biolabs

Creative Biolabs' CAR expression test services employ a comprehensive array of analytical approaches to quantify cell-surface CAR expression, delivering robust data on both the percentage of CAR-positive cells and the intensity of CAR signal. Tailored to the architecture of each CAR and the specific objectives of your study, we provide the most appropriate and rigorously validated detection strategy.

What we can offer

Assessment of CAR expression represents an essential phase in the development of CAR-T cell therapies. Creative Biolabs employs a suite of advanced analytical methods to accurately detect and quantify CAR expression levels, supporting critical quality attribute assessments throughout the therapeutic development process. Available techniques include:

Moreover, we offer bespoke CAR-specific monoclonal antibody development services to detect the expression of the CAR.

Our Service Process

Required Starting Materials:

• A CAR-T cell construct vector.
• The specific T cell or other immune cell samples.
• Details on the target antigen(s) for the CAR.

Key steps:

Final Deliverables: Upon project completion, you will receive raw data files, a comprehensive analysis report with supporting graphs and tables, and a final summary report.

Case Study

The following data exemplify typical experimental outcomes for CAR expression profiling.

FAQ

Why Choose Us?

Leveraging deep-domain expertise and state-of-the-art analytical platforms, we tailor fit-for-purpose assays to the unique architecture of your CAR construct. Our long-standing experience in assay design and validation consistently delivers precise, reproducible data that robustly underpins every stage of your CAR-T development program.

Customer Reviews

"The specificity of Creative Biolabs' antigen-based detection reagents is unparalleled. We've seen a significant reduction in the false-positive background staining that plagued our previous assays. It's truly streamlined our quality control workflow. " -J***n S.

"Using Creative Biolabs' CAR Expression Test Services in our research has significantly improved our ability to monitor CAR-T cell persistence at very low concentrations using qPCR. It provides the sensitivity and reliability we need for our long-term in vivo studies." -M***a T.

"The expertise of the Creative Biolabs team was invaluable in developing a custom linker antibody for our unique CAR construct. It saved us months of in-house development time and provided a consistent detection tool across our entire project pipeline." -S***h A.

How to contact us?

Our service integrates advanced technologies with deep scientific acumen to deliver reliable, high-resolution, and fully integrated data packages that propel your CAR-T cell therapy programs.

For detailed information or to schedule a project-specific consultation, please contact us.

References

1. Hu, Yifei, and Jun Huang. "The Chimeric Antigen Receptor Detection Toolkit." Frontiers in immunology vol. 11 1770. https://doi.org/10.3389/fimmu.2020.01770.
2. Kang, Chung Hyo et al. "c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer." Cancers vol. 13,22 5738. https://doi.org/10.3390/cancers13225738.
3. Reichman, Avinoam et al. "Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells." International journal of molecular sciences vol. 23,2 903. https://doi.org/10.3390/ijms23020903.
4. Distributed under Open Access License CC BY 4.0, without modification.